次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

核医学・放射性医薬品の世界市場:タイプ別、用途別2023年予測

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023

出版元:MarketsandMarketsLinkIcon出版元について
発行年:2018年6月
定価 Single User License(1名様ライセンス)US$5,650(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文 214ページになります。
商品コード:MAM1112

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
核医学・放射性医薬品の世界市場規模は2018年段階の推計39億5000万ドルから、今後2023年には52億6000万ドル市場に達すると予測されます。
当レポートでは、2023年に至る核医学・放射性医薬品の世界市場予測(市場規模US$)、タイプ別市場(診断用核医学各種、治療用核医学各種)、用途別市場(診断用途各種、治療用途各種)、処置数予測(診断処置各種、治療処置各種)、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業9社プロフィール動向などの情報も交えて、核医学・放射性医薬品市場の現在と今後展開を予測分析していきます。

【レポート構成概要】pic06_hc.jpg
◆ 核医学・放射性医薬品の世界市場予測2016-2023年
・市場規模(US$)

◆ タイプ別、市場-2023年
<診断用核医学>
SPECT用放射性医薬品
・99m Tc
・201Tl
・67Ga
・123I
・その他SPECT同位体
PET用放射性医薬品
・18F
・82Ru
・その他PET同位体

<治療用核医学>
α放射体
・223Ra
β放射体
・131I
・90Y
・153Sm
・186Re
・177Lu
・その他β放射体
密封小線源治療同位体
・125I
・192Ir
・103Pd
・131Cs
・その他密封小線源治療同位体

※(市場規模US$) 


◆ 用途別、市場-2023年
<診断用途>
SPECT
・心臓病学
・リンパ腫
・神経学
・甲状腺
・その他のSPECT用途
PET
・腫瘍学
・心臓病学
・神経学
・その他PET用途

<治療用途>
甲状腺
転移性骨腫瘍
リンパ腫
内分泌腫瘍
その他治療用途

※(市場規模US$) 

◆ 核医学核医学・放射性医薬品、処置数予測-2023年
診断処置
・SPECT用放射性医薬品
・PET用放射性医薬品
治療処置
・α放射体
・β放射体
・密封小線源治療同位体
※処置数データ掲載 

◆主要国地域別市場-2023年
北米
・米国、カナダ
欧州
・ドイツ、フランス、英国
・イタリア、スペイン
アジア太平洋
その他地域
※ 国地域別にタイプ別、用途別の細分化データ掲載、詳細は目次参照
※(市場規模US$)

◆市場分析
・市場ダイナミクス(ドライバー、障壁、機会、課題)
・市場シェア分析
・競合状況

◆ 核医学・放射性医薬品の主要企業プロフィール動向
・CARDINAL HEALTH
・GE HEALTHCARE (A FULLY-OWNED SUBSIDIARY OF GENERAL ELECTRIC COMPANY)
・CURIUM
・LANTHEUS MEDICAL IMAGING
・BAYER
・BRACCO IMAGING
・ECZACIBASI-MONROL NUCLEAR PRODUCTS
・NORDION (A SUBSIDIARY OF STERIGENICS INTERNATIONAL)
・ADVANCED ACCELERATOR APPLICATIONS (AAA, ACQUIRED BY NOVARTIS)

(全214頁)
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT (Technetium), PET (F-18)), Therapeutic (Beta Emitters (I-131), Alpha Emitters, Brachytherapy(Y-90))), Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2023

Table of Contents

1 INTRODUCTION 20

1.1 OBJECTIVES OF STUDY 20
1.2 MARKET DEFINITION 20
1.3 MARKET SCOPE 21
1.3.1 MARKETS COVERED 21
1.3.2 YEARS CONSIDERED FOR THE STUDY 22
1.4 CURRENCY 22
1.5 LIMITATIONS 22
1.6 STAKEHOLDERS 22

2 RESEARCH METHODOLOGY 23

2.1 RESEARCH METHODOLOGY STEPS 23
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 24
2.2.1 SECONDARY RESEARCH 24
2.2.1.1 Key data from secondary sources 24
2.2.2 PRIMARY RESEARCH 25
2.2.2.1 Key insights from primary sources 26
2.3 MARKET SIZE ESTIMATION METHODOLOGY 27
2.4 MARKET DATA VALIDATION AND TRIANGULATION 29
2.5 ASSUMPTIONS FOR THE STUDY 30

3 EXECUTIVE SUMMARY 31
4 PREMIUM INSIGHTS 34

4.1 NUCLEAR MEDICINE: MARKET OVERVIEW 34
4.2 GEOGRAPHIC ANALYSIS: NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS,
BY TYPE (2017) 35
4.3 NUCLEAR MEDICINE MARKET SHARE, BY TYPE, 2018 VS. 2023 36
4.4 GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE MARKET 37

5 MARKET OVERVIEW 38

5.1.1 INTRODUCTION 38
5.1.2 MARKET DYNAMICS 38
5.1.3 DRIVERS 39
5.1.3.1 Increasing incidence and prevalence of target conditions 39
5.1.3.2 Alpha radioimmunotherapy-based targeted cancer treatment 39
5.1.3.3 Initiatives to lessen the demand-supply gap of Mo-99 39
5.1.4 RESTRAINTS 40
5.1.4.1 Short half-life of radiopharmaceuticals 40
5.1.5 OPPORTUNITIES 40
5.1.5.1 Use of radiopharmaceuticals in neurological applications 40
5.1.6 CHALLENGES 41
5.1.6.1 Hospital budget cuts and high equipment prices 41

6 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE 42

6.1 INTRODUCTION 43
6.2 DIAGNOSTIC NUCLEAR MEDICINE 44
6.2.1 SPECT RADIOPHARMACEUTICALS 46
6.2.1.1 Tc-99m 49
6.2.1.2 Tl-201 50
6.2.1.3 Ga-67 51
6.2.1.4 I-123 53
6.2.1.5 Other SPECT isotopes 54
6.2.2 PET RADIOPHARMACEUTICALS 55
6.2.2.1 F-18 58
6.2.2.2 Ru-82 59
6.2.2.3 Other PET isotopes 61
6.3 THERAPEUTIC NUCLEAR MEDICINE 62
6.3.1 ALPHA EMITTERS 64
6.3.1.1 Ra-223 64
6.3.2 BETA EMITTERS 66
6.3.2.1 I-131 67
6.3.2.2 Y-90 69
6.3.2.3 Sm-153 70
6.3.2.4 Re-186 72
6.3.2.5 Lu-177 73
6.3.2.6 Other beta emitters 74
6.3.3 BRACHYTHERAPY ISOTOPES 76
6.3.3.1 I-125 78
6.3.3.2 Ir-192 79
6.3.3.3 Pd-103 81
6.3.3.4 Cs-131 82
6.3.3.5 Other brachytherapy isotopes 84

7 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION 87

7.1 INTRODUCTION 88
7.2 DIAGNOSTIC APPLICATIONS 88
7.2.1 SPECT APPLICATIONS 88
7.2.1.1 Cardiology 90
7.2.1.2 Lymphoma 91
7.2.1.3 Neurology 91
7.2.1.4 Thyroid 92
7.2.1.5 Other SPECT applications 93
7.2.2 PET APPLICATIONS 93
7.2.2.1 Oncology 95
7.2.2.2 Cardiology 96
7.2.2.3 Neurology 96
7.2.2.4 Other PET applications 97
7.3 THERAPEUTIC APPLICATIONS 97
7.3.1 THYROID 99
7.3.2 BONE METASTASIS 100
7.3.3 LYMPHOMA 101
7.3.4 ENDOCRINE TUMORS 101
7.3.5 OTHER THERAPEUTIC APPLICATIONS 102

8 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET,

BY PROCEDURAL VOLUME 103
8.1 INTRODUCTION 104
8.2 DIAGNOSTIC PROCEDURES 105
8.2.1 SPECT RADIOPHARMACEUTICALS 106
8.2.2 PET RADIOPHARMACEUTICALS 107
8.3 THERAPEUTIC PROCEDURES 108
8.3.1 BETA EMITTERS 109
8.3.2 ALPHA EMITTERS 110
8.3.3 BRACHYTHERAPY ISOTOPES 111

9 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY REGION 112

9.1 INTRODUCTION 113
9.2 NORTH AMERICA 114
9.2.1 US 119
9.2.2 CANADA 124
9.3 EUROPE 128
9.3.1 GERMANY 134
9.3.2 FRANCE 139
9.3.3 UK 143
9.3.4 ITALY 148
9.3.5 SPAIN 152
9.3.6 ROE 156
9.4 ASIA PACIFIC 161
9.5 REST OF THE WORLD 167

10 COMPETITIVE LANDSCAPE 173

10.1 OVERVIEW 173
10.2 MARKET SHARE ANALYSIS 174
10.3 COMPETITIVE SCENARIO 176
10.3.1 AGREEMENTS, PARTNERSHIPS, AND CONTRACTS 176
10.3.2 PRODUCT APPROVALS 177
10.3.3 FUNDING 177
10.3.4 ACQUISITIONS 178
10.3.5 EXPANSIONS 178
10.3.6 OTHER DEVELOPMENTS 179

11 COMPANY PROFILES 180

(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
11.1 CARDINAL HEALTH 180
11.2 GE HEALTHCARE (A FULLY-OWNED SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 183
11.3 CURIUM 186
11.4 LANTHEUS MEDICAL IMAGING 189
11.5 BAYER 192
11.6 BRACCO IMAGING 194
11.7 ECZACIBASI-MONROL NUCLEAR PRODUCTS 195
11.8 NORDION (A SUBSIDIARY OF STERIGENICS INTERNATIONAL) 197
11.9 ADVANCED ACCELERATOR APPLICATIONS (AAA, ACQUIRED BY NOVARTIS) 199
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 203

LIST OF TABLES

TABLE 1 NEW REACTORS EXPECTED TO OPEN DURING THE FORECAST PERIOD 40
TABLE 2 NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 43
TABLE 3 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 44
TABLE 4 DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY REGION,
2016–2023 (USD MILLION) 45
TABLE 5 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 45
TABLE 6 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 46
TABLE 7 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016–2023 (USD MILLION) 47
TABLE 8 SPECT RADIOPHARMACEUTICALS MARKET, BY REGION,
2016–2023 (USD MILLION) 47
TABLE 9 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 48
TABLE 10 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 48
TABLE 11 TC-99M MARKET, BY REGION, 2016–2023 (USD MILLION) 49
TABLE 12 NORTH AMERICA: TC-99M MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 49
TABLE 13 EUROPE: TC-99M MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 50
TABLE 14 TL-201 MARKET, BY REGION, 2016–2023 (USD MILLION) 50
TABLE 15 NORTH AMERICA: TL-201 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 51
TABLE 16 EUROPE: TL-201 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 51
TABLE 17 GA-67 MARKET, BY REGION, 2016–2023 (USD MILLION) 52
TABLE 18 NORTH AMERICA: GA-67 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 52
TABLE 19 EUROPE: GA-67 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 52
TABLE 20 I-123 MARKET, BY REGION, 2016–2023 (USD MILLION) 53
TABLE 21 NORTH AMERICA: I-123 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 53
TABLE 22 EUROPE: I-123 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 54
TABLE 23 OTHER SPECT ISOTOPES MARKET, BY REGION, 2016–2023 (USD MILLION) 54
TABLE 24 NORTH AMERICA: OTHER SPECT ISOTOPES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 55
TABLE 25 EUROPE: OTHER SPECT ISOTOPES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 55
TABLE 26 PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016–2023 (USD MILLION) 56
TABLE 27 PET RADIOPHARMACEUTICALS MARKET, BY REGION, 2016–2023 (USD MILLION) 56
TABLE 28 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 57
TABLE 29 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 57
TABLE 30 F-18 MARKET, BY REGION, 2016–2023 (USD MILLION) 58
TABLE 31 NORTH AMERICA: F-18 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 58
TABLE 32 EUROPE: F-18 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 59
TABLE 33 RU-82 MARKET, BY REGION, 2016–2023 (USD MILLION) 59
TABLE 34 NORTH AMERICA: RU-82 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 60
TABLE 35 EUROPE: RU-82 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 60
TABLE 36 OTHER PET ISOTOPES MARKET, BY REGION, 2016–2023 (USD MILLION) 61
TABLE 37 NORTH AMERICA: OTHER PET ISOTOPES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 61
TABLE 38 EUROPE: OTHER PET ISOTOPES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 62
TABLE 39 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 63
TABLE 40 THERAPEUTIC NUCLEAR MEDICINE MARKET, BY REGION,
2016–2023 (USD MILLION) 63
TABLE 41 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 63
TABLE 42 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 64
TABLE 43 RA-223 MARKET, BY REGION, 2016–2023 (USD MILLION) 65
TABLE 44 NORTH AMERICA: RA-223 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 65
TABLE 45 EUROPE: RA-223 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 65
TABLE 46 BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 66
TABLE 47 BETA EMITTERS MARKET, BY REGION, 2016–2023 (USD MILLION) 66
TABLE 48 NORTH AMERICA: BETA EMITTERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 67
TABLE 49 EUROPE: BETA EMITTERS MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 67
TABLE 50 I-131 MARKET, BY REGION, 2016–2023 (USD MILLION) 68
TABLE 51 NORTH AMERICA: I-131 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 68
TABLE 52 EUROPE: I-131 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 68
TABLE 53 Y-90 MARKET, BY REGION, 2016–2023 (USD MILLION) 69
TABLE 54 NORTH AMERICA: Y-90 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 69
TABLE 55 EUROPE: Y-90 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 70
TABLE 56 SM-153 MARKET, BY REGION, 2016–2023 (USD MILLION) 70
TABLE 57 NORTH AMERICA: SM-153 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 71
TABLE 58 EUROPE: SM-153 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 71
TABLE 59 RE-186 MARKET, BY REGION, 2016–2023 (USD MILLION) 72
TABLE 60 NORTH AMERICA: RE-186 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 72
TABLE 61 EUROPE: RE-186 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 73
TABLE 62 LU-177 MARKET, BY REGION, 2016–2023 (USD MILLION) 73
TABLE 63 NORTH AMERICA: LU-177 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 74
TABLE 64 EUROPE: LU-177 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 74
TABLE 65 OTHER BETA EMITTERS MARKET, BY REGION, 2016–2023 (USD MILLION) 75
TABLE 66 NORTH AMERICA: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 75
TABLE 67 EUROPE: OTHER BETA EMITTERS MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 75
TABLE 68 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016–2023 (USD MILLION) 76
TABLE 69 BRACHYTHERAPY ISOTOPES MARKET, BY REGION, 2016–2023 (USD MILLION) 77
TABLE 70 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 77
TABLE 71 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 77
TABLE 72 I-125 MARKET, BY REGION, 2016–2023 (USD MILLION) 78
TABLE 73 NORTH AMERICA: IODINE-125 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 78
TABLE 74 EUROPE: IODINE-125 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 79
TABLE 75 IR-192 MARKET, BY REGION, 2016–2023 (USD MILLION) 79
TABLE 76 NORTH AMERICA: IR-192 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 80
TABLE 77 EUROPE: IR-192 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 80
TABLE 78 PD-103 MARKET, BY REGION, 2016–2023 (USD MILLION) 81
TABLE 79 NORTH AMERICA: PD-103 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 81
TABLE 80 EUROPE: PD-103 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 82
TABLE 81 CS-131 MARKET, BY REGION, 2016–2023 (USD MILLION) 82
TABLE 82 NORTH AMERICA: CS-131 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 83
TABLE 83 EUROPE: CS-131 MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 83
TABLE 84 OTHER BRACHYTHERAPY ISOTOPES MARKET, BY REGION,
2016–2023 (USD MILLION) 84
TABLE 85 NORTH AMERICA: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 84
TABLE 86 EUROPE: OTHER BRACHYTHERAPY ISOTOPES MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 85
TABLE 87 SPECT APPLICATIONS MARKET, BY TYPE, 2016–2023 (USD MILLION) 89
TABLE 88 SPECT APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 90
TABLE 89 CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 90
TABLE 90 LYMPHOMA APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 91
TABLE 91 NEUROLOGY APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 91
TABLE 92 THYROID APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 92
TABLE 93 OTHER SPECT APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 93
TABLE 94 PET APPLICATIONS MARKET, BY TYPE, 2016–2023 (USD MILLION) 94
TABLE 95 PET APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 95
TABLE 96 ONCOLOGY APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 95
TABLE 97 CARDIOLOGY APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 96
TABLE 98 NEUROLOGY APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 96
TABLE 99 OTHER PET APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 97
TABLE 100 THERAPEUTIC APPLICATIONS MARKET, BY TYPE, 2016–2023 (USD MILLION) 98
TABLE 101 THERAPEUTIC APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 99
TABLE 102 THYROID APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 99
TABLE 103 BONE METASTASIS APPLICATIONS MARKET, BY REGION,
2016–2023 (USD MILLION) 100
TABLE 104 LYMPHOMA APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 101
TABLE 105 ENDOCRINE APPLICATIONS MARKET, BY REGION, 2016–2023 (USD MILLION) 101
TABLE 106 OTHER THERAPEUTIC APPLICATIONS MARKET, BY REGION,
2016–2023 (USD MILLION) 102
TABLE 107 NUCLEAR MEDICINE PROCEDURES MARKET, BY TYPE,
2016–2023 (THOUSAND PROCEDURES) 104
TABLE 108 NUCLEAR MEDICINE PROCEDURES MARKET, BY REGION,
2016–2023 (THOUSAND PROCEDURES) 105
TABLE 109 DIAGNOSTIC PROCEDURES MARKET, BY TYPE,
2016–2023 (THOUSAND PROCEDURES) 105
TABLE 110 DIAGNOSTIC PROCEDURES MARKET, BY REGION,
2016–2023 (THOUSAND PROCEDURES) 106
TABLE 111 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (THOUSAND PROCEDURES) 106
TABLE 112 SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE, BY REGION,
2016–2023 (THOUSAND PROCEDURES) 107
TABLE 113 PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (THOUSAND PROCEDURES) 107
TABLE 114 PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (THOUSAND PROCEDURES) 108
TABLE 115 THERAPEUTIC PROCEDURES MARKET, BY TYPE,
2016–2023 (THOUSAND PROCEDURES) 108
TABLE 116 THERAPEUTIC PROCEDURES MARKET, BY REGION,
2016–2023 (THOUSAND PROCEDURES) 109
TABLE 117 BETA EMITTERS MARKET, BY TYPE, 2016–2023 (THOUSAND PROCEDURES) 109
TABLE 118 BETA EMITTERS MARKET, BY REGION, 2016–2023 (THOUSAND PROCEDURES) 110
TABLE 119 ALPHA EMITTERS MARKET, BY REGION, 2016–2023 (THOUSAND PROCEDURES) 110
TABLE 120 BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2016–2023 (THOUSAND PROCEDURES) 111
TABLE 121 BRACHYTHERAPY ISOTOPES MARKET, BY REGION,
2016–2023 (THOUSAND PROCEDURES) 111
TABLE 122 NUCLEAR MEDICINE MARKET, BY REGION, 2016–2023 (USD MILLION) 113
TABLE 123 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY COUNTRY,
2016–2023 (USD MILLION) 115
TABLE 124 NORTH AMERICA: NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 115
TABLE 125 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE MARKET,
BY TYPE, 2016–2023 (USD MILLION) 115
TABLE 126 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY TYPE, 2016–2023 (USD MILLION) 116
TABLE 127 NORTH AMERICA: SPECT RADIOPHARMACEUTICALS MARKET,
BY APPLICATION, 2016–2023 (USD MILLION) 116
TABLE 128 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 117
TABLE 129 NORTH AMERICA: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 117
TABLE 130 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 117
TABLE 131 NORTH AMERICA: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 118
TABLE 132 NORTH AMERICA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2016–2023 (USD MILLION) 118
TABLE 133 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 119
TABLE 134 US: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 120
TABLE 135 US: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 120
TABLE 136 US: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 121
TABLE 137 US: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 121
TABLE 138 US: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016–2023 (USD MILLION) 121
TABLE 139 US: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 122
TABLE 140 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 122
TABLE 141 US: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 142 US: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016–2023 (USD MILLION) 123
TABLE 143 US: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 124
TABLE 144 CANADA: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 125
TABLE 145 CANADA: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 125
TABLE 146 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 125
TABLE 147 CANADA: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 126
TABLE 148 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 126
TABLE 149 CANADA: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 126
TABLE 150 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 127
TABLE 151 CANADA: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 127
TABLE 152 CANADA: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2016–2023 (USD MILLION) 128
TABLE 153 CANADA: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 128
TABLE 154 EUROPE: NUCLEAR MEDICINE MARKET, BY COUNTRY, 2016–2023 (USD MILLION) 130
TABLE 155 EUROPE: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 130
TABLE 156 EUROPE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 130
TABLE 157 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 131
TABLE 158 EUROPE: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 131
TABLE 159 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 132
TABLE 160 EUROPE: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 132
TABLE 161 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 132
TABLE 162 EUROPE: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 133
TABLE 163 EUROPE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2016–2023 (USD MILLION) 133
TABLE 164 EUROPE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 134
TABLE 165 GERMANY: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 135
TABLE 166 GERMANY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 135
TABLE 167 GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 135
TABLE 168 GERMANY: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 136
TABLE 169 GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 136
TABLE 170 GERMANY: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 136
TABLE 171 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 137
TABLE 172 GERMANY: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 137
TABLE 173 GERMANY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2016–2023 (USD MILLION) 138
TABLE 174 GERMANY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 138
TABLE 175 FRANCE: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 139
TABLE 176 FRANCE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 140
TABLE 177 FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 140
TABLE 178 FRANCE: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 141
TABLE 179 FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 141
TABLE 180 FRANCE: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 141
TABLE 181 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 142
TABLE 182 FRANCE: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 142
TABLE 183 FRANCE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2016–2023 (USD MILLION) 143
TABLE 184 FRANCE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 143
TABLE 185 UK: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 144
TABLE 186 UK: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 144
TABLE 187 UK: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 145
TABLE 188 UK: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 145
TABLE 189 UK: PET RADIOPHARMACEUTICALS MARKET, BY TYPE, 2016–2023 (USD MILLION) 146
TABLE 190 UK: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 146
TABLE 191 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 146
TABLE 192 UK: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 147
TABLE 193 UK: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016–2023 (USD MILLION) 147
TABLE 194 UK: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 148
TABLE 195 ITALY: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 148
TABLE 196 ITALY: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 149
TABLE 197 ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 149
TABLE 198 ITALY: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 149
TABLE 199 ITALY: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 150
TABLE 200 ITALY: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 150
TABLE 201 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 150
TABLE 202 ITALY: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 151
TABLE 203 ITALY: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016–2023 (USD MILLION) 151
TABLE 204 ITALY: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 152
TABLE 205 SPAIN: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 153
TABLE 206 SPAIN: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 153
TABLE 207 SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 153
TABLE 208 SPAIN: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 154
TABLE 209 SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 154
TABLE 210 SPAIN: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 154
TABLE 211 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 155
TABLE 212 SPAIN: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 155
TABLE 213 SPAIN: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016–2023 (USD MILLION) 156
TABLE 214 SPAIN: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 156
TABLE 215 ROE: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 157
TABLE 216 ROE: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 157
TABLE 217 ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 158
TABLE 218 ROE: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 158
TABLE 219 ROE: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 158
TABLE 220 ROE: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 159
TABLE 221 ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 159
TABLE 222 ROE: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 160
TABLE 223 ROE: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016–2023 (USD MILLION) 160
TABLE 224 ROE: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 161
TABLE 225 ASIA PACIFIC: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 163
TABLE 226 ASIA PACIFIC: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 163
TABLE 227 ASIA PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 163
TABLE 228 ASIA PACIFIC: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 164
TABLE 229 ASIA PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 164
TABLE 230 ASIA PACIFIC: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 165
TABLE 231 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 165
TABLE 232 ASIA PACIFIC: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 166
TABLE 233 ASIA PACIFIC: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE,
2016–2023 (USD MILLION) 166
TABLE 234 ASIA PACIFIC: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION, 2016–2023 (USD MILLION) 167
TABLE 235 ROW: NUCLEAR MEDICINE MARKET, BY TYPE, 2016–2023 (USD MILLION) 169
TABLE 236 ROW: DIAGNOSTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 237 ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 169
TABLE 238 ROW: SPECT RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 170
TABLE 239 ROW: PET RADIOPHARMACEUTICALS MARKET, BY TYPE,
2016–2023 (USD MILLION) 170
TABLE 240 ROW: PET RADIOPHARMACEUTICALS MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 170
TABLE 241 ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY TYPE,
2016–2023 (USD MILLION) 171
TABLE 242 ROW: BETA EMITTERS MARKET, BY TYPE, 2016–2023 (USD MILLION) 171
TABLE 243 ROW: BRACHYTHERAPY ISOTOPES MARKET, BY TYPE, 2016–2023 (USD MILLION) 172
TABLE 244 ROW: THERAPEUTIC NUCLEAR MEDICINE MARKET, BY APPLICATION,
2016–2023 (USD MILLION) 172
TABLE 245 AGREEMENTS, PARTNERSHIPS, AND CONTRACTS (2015–2018) 176
TABLE 246 PRODUCT APPROVALS (2015–2018) 177
TABLE 247 FUNDING (2015–2018) 177
TABLE 248 ACQUISITIONS (2015–2018) 178
TABLE 249 EXPANSIONS (2015–2018) 178
TABLE 250 OTHER DEVELOPMENTS (2015–2018) 179

LIST OF FIGURES

FIGURE 1 GLOBAL NUCLEAR MEDICINE MARKET: RESEARCH METHODOLOGY 23
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 26
FIGURE 3 BOTTOM-UP APPROACH 27
FIGURE 4 TOP-DOWN APPROACH 28
FIGURE 5 RESEARCH DESIGN 28
FIGURE 6 DATA TRIANGULATION METHODOLOGY 29
FIGURE 7 NUCLEAR MEDICINE MARKET, BY TYPE, 2018 VS. 2023 (USD MILLION) 31
FIGURE 8 NUCLEAR MEDICINE MARKET FOR SPECT APPLICATIONS, BY TYPE,
2018 VS. 2023 (USD MILLION) 32
FIGURE 9 NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS, BY TYPE,
2018 VS. 2023 (USD MILLION) 33
FIGURE 10 RISING INCIDENCE & PREVALENCE OF CANCER & CARDIOVASCULAR DISEASES—KEY FACTOR SUPPORTING MARKET GROWTH DURING THE FORECAST PERIOD 34
FIGURE 11 ONCOLOGY SEGMENT DOMINATED THE NUCLEAR MEDICINE MARKET FOR PET APPLICATIONS IN 2017 35
FIGURE 12 DIAGNOSTICS SEGMENT WILL CONTINUE TO DOMINATE THE NUCLEAR MEDICINE MARKET IN 2023 36
FIGURE 13 ASIA PACIFIC TO WITNESS THE HIGHEST GROWTH IN THE NUCLEAR MEDICINE MARKET DURING THE FORECAST PERIOD 37
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
FIGURE 15 DIAGNOSTIC NUCLEAR MEDICINE SEGMENT COMMANDED THE LARGEST SHARE OF THE NUCLEAR MEDICINE MARKET IN 2017 43
FIGURE 16 PET RADIOPHARMACEUTICALS TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 44
FIGURE 17 ALPHA EMITTERS WILL CONTINUE TO DOMINATE THE THERAPEUTIC NUCLEAR MEDICINE MARKET DURING THE FORECAST PERIOD 62
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE NUCLEAR MEDICINE MARKET 85
FIGURE 19 THYROID SEGMENT IS EXPECTED TO REGISTER THE HIGHEST CAGR IN THE SPECT APPLICATIONS MARKET DURING THE FORECAST PERIOD 89
FIGURE 20 ONCOLOGY APPLICATIONS SEGMENT IS EXPECTED TO GROW AT THE HIGHEST CAGR IN THE PET APPLICATIONS MARKET DURING THE FORECAST PERIOD 94
FIGURE 21 ENDOCRINE TUMORS APPLICATION SEGMENT IS EXPECTED TO REGISTER THE HIGHEST CAGR IN THE THERAPEUTIC APPLICATIONS MARKET DURING THE FORECAST PERIOD 98
FIGURE 22 NUCLEAR MEDICINE PROCEDURES MARKET, BY TYPE,
2018 VS. 2023 (THOUSAND PROCEDURES) 104
FIGURE 23 NORTH AMERICA TO DOMINATE THE NUCLEAR MEDICINE MARKET IN 2018 113
FIGURE 24 NORTH AMERICA: NUCLEAR MEDICINE MARKET SNAPSHOT 114
FIGURE 25 EUROPE: NUCLEAR MEDICINE MARKET SNAPSHOT 129
FIGURE 26 ASIA PACIFIC: NUCLEAR MEDICINE MARKET SNAPSHOT 162
FIGURE 27 ROW: NUCLEAR MEDICINE MARKET SNAPSHOT 168
FIGURE 28 KEY DEVELOPMENTS IN THE NUCLEAR MEDICINE MARKET, 2015–2018 173
FIGURE 29 MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2017 174
FIGURE 30 CARDINAL HEALTH: COMPANY SNAPSHOT (2017) 180
FIGURE 31 GE HEALTHCARE: COMPANY SNAPSHOT (2017) 183
FIGURE 32 LANTHEUS MEDICAL IMAGING: COMPANY SNAPSHOT (2017) 189
FIGURE 33 BAYER: COMPANY SNAPSHOT (2017) 192
FIGURE 34 ADVANCED ACCELERATOR APPLICATIONS: COMPANY SNAPSHOT (2016) 199

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。